Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | ACACB | O00763 | 9/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ETV6 | P41212 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668287 | 0.91 | GPR119 (0.46) | GPR119KDRETV6RORCKMT2A | |
| SCHEMBL1670864 | 0.89 | GPR119 (0.46) | GPR119MEN1KMT2A | |
| SCHEMBL1668753 | 0.89 | GPR119 (0.46) | GPR119KDRETV6RORCMEN1 | |
| SCHEMBL1668953 | 0.89 | GPR119 (0.47) | GPR119KDRETV6RORC | |
| SCHEMBL15368999 | 0.89 | GPR119 (0.46) | GPR119ACACBKDRETV6RORC | |
| SCHEMBL1668667 | 0.87 | PANK3 (0.43) | GPR119ACACBKDRETV6RORC | |
| SCHEMBL1668307 | 0.87 | KDR (0.45) | GPR119ACACBKDRETV6MEN1 | |
| SCHEMBL1670031 | 0.86 | KDM4E (0.51) | GPR119ACACB | |
| SCHEMBL2508495 | 0.86 | CHRM2 (0.44) | GPR119PANK3 | |
| SCHEMBL1668471 | 0.85 | EED (0.48) | ACACBRORCMEN1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | claimed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | claimed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| US-8575168-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2013-11-05 | — | — | US | disclosed |
| EP-2486033-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-15 | — | — | EP | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-06 | — | — | US | disclosed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044001-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245220-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | GPR119 1/4885ACACB 1289/4885KDR 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.